PDIA3 and neoplasm: However, ERp57 exerts the opposite effect on gastric cancer progression; its expression is significantly decreased in gastric cancer and metastases, and low levels of ERp57 are correlated with an increased depth of tumor invasion and advanced disease stage 37.